首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1922764

日本疼痛管理藥物市場規模、佔有率、趨勢及預測（按藥物類別、適應症、通路和地區分類，2026-2034年）

Japan Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本疼痛管理藥物市場規模達43.219億美元。 IMARC Group預測，到2034年，該市場規模將達到52.72億美元，2026年至2034年的複合年成長率（CAGR）為2.23%。該市場正經歷顯著成長，主要促進因素包括人口老化、藥物輸送技術的創新以及對非鴉片類藥物治療需求的不斷成長。此外，嚴格的監管和醫療體系改革也在持續推動全國範圍內的市場擴張和治療方法的進步。

日本疼痛管理藥物市場趨勢：

人口老化加劇

日本人口老化是疼痛管理藥物產業持續需求的關鍵促進因素。骨關節炎、慢性背痛和神經病變疾病等與老齡化相關的健康問題的日益增多，直接影響日本疼痛管理藥物市場的成長。報告顯示，日本老年人口已達到創紀錄的3,625萬，佔總人口的29.3%。其中，65歲及以上的老年人口中，女性2053萬，男性1572萬。此外，914萬老年人仍在工作，凸顯了在連續13年人口下降的情況下，日本面臨的持續人口結構挑戰。作為世界上預期壽命最高的國家之一，日本很大一部分人口需要長期、永續的疼痛緩解治療，這通常涉及非類固醇消炎劑（NSAIDs）、抗憂鬱症和老年專用藥物的聯合治療方法。老年患者更容易出現藥物過敏和副作用。醫療機構正透過優先研發更安全、低劑量的藥物配方和完善的監測通訊協定來應對這項挑戰。此外，關節重建等與老齡化相關的手術數量增加，也推動了術後止痛藥物的需求。隨著日本人口結構變化的加深，這一趨勢將繼續擴大其在日本疼痛管理藥物市場各個治療領域的佔有率。

藥物遞送和製劑方面的創新

日本製藥公司正積極探索藥物遞送方式的創新，以改善治療效果和病患舒適度。隨著對慢性疼痛和老年護理的日益關注，製藥領域正轉向採用經皮貼片、緩釋片、外用凝膠和噴霧等先進製劑。這些替代製劑能夠更精準地控制劑量，持續緩解疼痛，並減少胃腸道和全身副作用，這對老年患者和長期用藥者尤其重要。製劑創新還包括開發複方藥物和新型化合物，以有效針對鎮痛並降低成癮風險。例如，2024年11月，Eisai在日本推出了Rosevalamin®注射液25mg（甲鈷胺），旨在延緩肌萎縮側索硬化症（ALS）患者的功能障礙進展並緩解疼痛。該產品於9月獲得核准，並在完成一項包含130名患者的III期臨床試驗後上市。這些進展不僅提高了患者的用藥依從性，也有助於拓展跨治療領域的產品線。隨著監管機構支持更安全的替代方案，醫療保健專業人員採用新的劑型，預計創新將在未來幾年對日本疼痛管理藥物市場的前景產生關鍵影響。

本報告解答的關鍵問題

日本疼痛管理藥物市場目前發展狀況如何？未來幾年又將如何發展？
日本的疼痛管理藥物市場是如何依藥物類別細分的？
日本疼痛管理藥物市場依適應症分類的組成是怎樣的？
日本疼痛管理藥物市場按通路分類的組成是怎樣的？
日本疼痛管理藥物市場按地區分類的情況如何？
請介紹日本疼痛管理藥物市場價值鏈的各個環節。
日本疼痛管理藥物市場的主要促進因素和挑戰是什麼？
日本疼痛管理藥物市場的結構是怎麼樣的？主要參與者有哪些？
日本疼痛管理藥物市場競爭程度如何？

The Japan pain management drugs market size reached USD 4,321.9 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 5,272.0 Million by 2034 , exhibiting a growth rate (CAGR) of 2.23% during 2026-2034 . The market is experiencing significant growth, driven by an aging population, innovation in drug delivery, and rising demand for non-opioid treatments. Moreover, strict regulations and healthcare reforms continue to shape market expansion and therapeutic advancements nationwide.

JAPAN PAIN MANAGEMENT DRUGS MARKET TRENDS:

Rising Geriatric Population

Japan's aging population is a significant driver of sustained demand in the pain management drugs industry. The increasing number of elderly individuals is directly influencing Japan pain management drugs market growth, as age-related health issues such as osteoarthritis, chronic back pain, and neuropathic conditions become more prevalent. According to the reports, Japan's elderly population reached a record 36.25 million, making up 29.3% of the total population. Women aged 65 or older account for 20.53 million, while men total 15.72 million. Additionally, 9.14 million elderly are employed, reflecting ongoing demographic challenges as the population declines for the 13th consecutive year. With life expectancy among the highest globally, a large segment of the population requires long-term, consistent pain relief therapies. These often include a combination of NSAIDs, antidepressants, and specialized treatments tailored to older adults, who are also more vulnerable to drug sensitivity and side effects. Healthcare providers are adapting by prioritizing safer, lower-dose formulations and monitoring protocols. Additionally, the rising rate of age-related surgeries, such as joint replacements, is fueling demand for post-operative pain medications. As Japan's demographic shift deepens, this trend will continue to increase the Japan pain management drugs market share across therapeutic categories.

To get more information on this market Request Sample

Innovation in Drug Delivery and Formulation

Japanese pharmaceutical companies are actively innovating drug delivery methods to improve treatment outcomes and enhance patient comfort. With a growing focus on chronic pain and elderly care, firms are shifting toward advanced options such as transdermal patches, extended-release tablets, and topical gels or sprays. These alternatives allow for more precise dosing, sustained pain relief, and reduced gastrointestinal or systemic side effects, which are particularly important for older adults and long-term users. Innovation in formulation also includes development of combination drugs and novel compounds that target pain more efficiently while reducing dependency risks. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan, to slow functional impairment and address pain in amyotrophic lateral sclerosis (ALS) patients. Approved in September, it follows a Phase III trial with 130 patients. These advancements are not only improving adherence but also expanding product offerings across therapeutic categories. As regulatory bodies support safer alternatives and healthcare professionals adopt newer delivery formats, innovation is expected to play a key role in shaping the Japan pain management drugs market outlook in the coming years.

JAPAN PAIN MANAGEMENT DRUGS MARKET SEGMENTATION:

Drug Class Insights:

NSAIDs
Anesthetics
Anticonvulsants
Antimigraine Agents
Antidepressants
Opioids
Others
NSAIDs
Anesthetics
Anticonvulsants
Antimigraine Agents
Antidepressants
Opioids
Others

Indication Insights:

Musculoskeletal Pain
Surgical and Trauma Pain
Cancer Pain
Neuropathic Pain
Migraine Pain
Obstetrical Pain
Fibromyalgia Pain
Burn Pain
Dental/Facial Pain
Pediatric Pain
Others
Musculoskeletal Pain
Surgical and Trauma Pain
Cancer Pain
Neuropathic Pain
Migraine Pain
Obstetrical Pain
Fibromyalgia Pain
Burn Pain
Dental/Facial Pain
Pediatric Pain
Others

Distribution Channel Insights:

Access the comprehensive market breakdown Request Sample
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan pain management drugs market performed so far and how will it perform in the coming years?
What is the breakup of the Japan pain management drugs market on the basis of drug class?
What is the breakup of the Japan pain management drugs market on the basis of indication?
What is the breakup of the Japan pain management drugs market on the basis of distribution channel?
What is the breakup of the Japan pain management drugs market on the basis of region?
What are the various stages in the value chain of the Japan pain management drugs market?
What are the key driving factors and challenges in the Japan pain management drugs market?
What is the structure of the Japan pain management drugs market and who are the key players?
What is the degree of competition in the Japan pain management drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pain Management Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pain Management Drugs Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Pain Management Drugs Market - Breakup by Drug Class

6.1 NSAIDs
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Anesthetics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Anticonvulsants
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Antimigraine Agents
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Antidepressants
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Opioids
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2020-2025)
- 6.6.3 Market Forecast (2026-2034)
6.7 Others
- 6.7.1 Historical and Current Market Trends (2020-2025)
- 6.7.2 Market Forecast (2026-2034)

7 Japan Pain Management Drugs Market - Breakup by Indication

7.1 Musculoskeletal Pain
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Surgical and Trauma Pain
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Cancer Pain
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Neuropathic Pain
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Migraine Pain
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Obstetrical Pain
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Fibromyalgia Pain
- 7.7.1 Overview
- 7.7.2 Historical and Current Market Trends (2020-2025)
- 7.7.3 Market Forecast (2026-2034)
7.8 Burn Pain
- 7.8.1 Overview
- 7.8.2 Historical and Current Market Trends (2020-2025)
- 7.8.3 Market Forecast (2026-2034)
7.9 Dental/Facial Pain
- 7.9.1 Overview
- 7.9.2 Historical and Current Market Trends (2020-2025)
- 7.9.3 Market Forecast (2026-2034)
7.10 Pediatric Pain
- 7.10.1 Overview
- 7.10.2 Historical and Current Market Trends (2020-2025)
- 7.10.3 Market Forecast (2026-2034)
7.11 Others
- 7.11.1 Historical and Current Market Trends (2020-2025)
- 7.11.2 Market Forecast (2026-2034)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)

9 Japan Pain Management Drugs Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Drug Class
- 9.1.4 Market Breakup by Indication
- 9.1.5 Market Breakup by Distribution Channel
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Drug Class
- 9.2.4 Market Breakup by Indication
- 9.2.5 Market Breakup by Distribution Channel
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Drug Class
- 9.3.4 Market Breakup by Indication
- 9.3.5 Market Breakup by Distribution Channel
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Drug Class
- 9.4.4 Market Breakup by Indication
- 9.4.5 Market Breakup by Distribution Channel
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Drug Class
- 9.5.4 Market Breakup by Indication
- 9.5.5 Market Breakup by Distribution Channel
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Drug Class
- 9.6.4 Market Breakup by Indication
- 9.6.5 Market Breakup by Distribution Channel
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Drug Class
- 9.7.4 Market Breakup by Indication
- 9.7.5 Market Breakup by Distribution Channel
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Drug Class
- 9.8.4 Market Breakup by Indication
- 9.8.5 Market Breakup by Distribution Channel
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Pain Management Drugs Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Products Offered
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Products Offered
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Products Offered
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Products Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Products Offered
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Pain Management Drugs Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis